Screener
Maravai LifeSciences Holdings, Inc. MRVI Corporate — Restructuring
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maravai LifeSciences Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Maravai LifeSciences Holdings, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001823239-26-000059
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 32,070 | 38,715 | 61,162 | 78,279 |
| Research and development | 3,702 | 4,882 | 7,591 | 9,770 |
| Goodwill impairment | — | 30,449 | — | 42,884 |
| Restructuring | (33) | — | 2,845 | — |
| Total operating expenses | 35,739 | 74,046 | 71,598 | 130,933 |
| Loss from operations | (15,089) | (66,278) | (17,247) | (115,440) |
| Other income (expense): | ||||
| Interest expense | (4,809) | (6,815) | (10,558) | (13,593) |
Item 1. Financial Statements
FAQ
- What is Maravai LifeSciences Holdings, Inc.'s corporate — restructuring?
- Maravai LifeSciences Holdings, Inc. (MRVI) reported corporate — restructuring of $126K in Q2 2026.
- What does corporate — restructuring mean?
- Aggregates all costs associated with reorganizing corporate operations to improve efficiency or align with strategic goals. This includes costs related to personnel changes, process re-engineering, and organizational realignment. It is a critical metric for assessing the financial impact of management's efforts to optimize the corporate cost structure.
Ask your AI about Maravai LifeSciences Holdings, Inc.'s corporate — restructuring.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude